Tag Archives: National Institute of Allergy and Infectious Diseases

Oracle Helps NIH Build Cloud-Based Clinical Trial Registry

health IT

Oracle has built a cloud application system for a National Institutes of Health component to identify qualified participants for large-scale clinical trials of vaccines and monoclonal antibody therapies for the novel coronavirus. The registry is designed to screen indviduals who have volunteered to join tests through the National Institutes of Allergy and Infectious Diseases' COVID-19 Prevention Network, Oracle said Thursday.

Read More »

NTT DATA Federal Arm Gets NIAID IT Help Desk Support Contract; Tim Conway Quoted

NTT DATA Services’ federal business has received a potential five-year, $60M contract to provide help desk and field services support for the National Institute of Allergy and Infectious Diseases. The contract covers the delivery of specialized and general IT management support to NIAID’s office of science management and operations to facilitate research efforts to treat and prevent allergic and immunologic diseases, the company said Thursday.

Read More »

Charles River Laboratories Begins Management Support Work for NIAID Under $96M Contract

Charles River Laboratories has started providing management support services and personnel to the National Institute of Allergy and Infectious Diseases under a potential five-year, $95.7M contract. The company said Tuesday its Insourcing Solutions business is supervising 200 of its staff tasked to support NIAID’s biomedical research operations across various scientific …

Read More »

HHS Orders Elusys Anthrax Treatment for Strategic National Stockpile

The Department of Health and Human Services has awarded Elusys Therapeutics a $25.2 million contract to supply an anthrax treatment for the country’s national repository of medical countermeasures for public health emergency use. HHS said Monday its Biomedical Advanced Research and Development Authority provided funds for the company to produce the Anthim monoclonal antibody injection as …

Read More »

CSRA Subsidary’s Plague Vaccine Receives FDA Orphan Drug Designation

A plague vaccine being developed by a CSRA subsidiary has received orphan drug status from the U.S. Food and Drug Administration as a treatment for pre-exposure prophlaxis of Yersinia pestis infection. CSRA said Wednesday its DynPort Vaccine Company works with the Defense Department on the development of the recombinant rF1V plague vaccine that will be added …

Read More »

MRIGlobal to Evaluate Tech, Specimen Processes for NIH Tuberculosis Research Initiatives

A National Institutes of Health division has awarded MRIGlobal a potential $ 13.7 million contract to provide evaluation services in support of research initiatives on Mycobacterium tuberculosis. The company said Feb. 1 it will work to analyze Mtb tools and specimen processes for National Institute of Allergy and Infectious Diseases clinical investigations …

Read More »

NIH’s NIAID Institute Seeks Strategic Planning, Analytical Support for Clinical Research Division

The National Institute of Health‘s National Institute of Allergy and Infectious Diseases has issued a sources sought notice to gather information on small businesses that can offer  support services to NIAID’s division of clinical research. NIAID DCR seeks contractor support in the administrative, analyses and reporting, management consulting, performance assessment, operational and resource planning areas, according …

Read More »

HHS to Fund Commercial Manufacturing Tests for BioProtection Systems’ Ebola Vaccine

The U.S. Department of Health and Human Services has awarded BioProtection Systems a contract with $24.75 million in base funds to support commercial manufacturing tests of the company’s anti-Ebola vaccine. HHS said Tuesday said the tests will work to validate whether manufacturing processes created under a previous contract would produce enough V920 vaccines in the event of …

Read More »

Hawaii Biotech Receives NIAID Grant for Chikungunya Virus Vaccine Development

Hawaii Biotech Inc. has been selected to develop a vaccine against chikungunya virus under a Small Business Innovation Research Phase I grant from the National Institutes of Health‘s National Institute of Allergy and Infectious Diseases. The biotechnology company said Tuesday it will collaborate with the Sabin Vaccine Institute and Baylor College of Medicine on the …

Read More »

NIH Allergy Institute Taps Emergent BioSolutions for Anthrax Vaccine Dry Formulation; Adam Havey Comments

Emergent BioSolutions has landed a five-year, $29 million contract with the National Institute of Allergy and Infectious Diseases to make a dry formulation of the NuThrax anthrax vaccine candidate in an effort to facilitate shipping and storage at normal temperatures. The company said Monday the contract covers manufacturing, non-clinical processes and application to the U.S. Food and Drug Administration for …

Read More »